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6/j.bInfection because of herpes simplex virus (HSV) that is resistant to acyclovir (ACV) poses treatment
challenges in hematopoietic cell transplant (HCT) patients. We present a series of patients with ACV-
resistant HSV following HCTwho were successfully treated with continuous infusion high-dose ACV after
failing standard treatment regimens for ACV-resistant HSV.
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In the immunocompromised population of alloge-
neic hematopoietic cell transplant (HCT) recipients,
herpes simplex virus (HSV) remains a common viral
infection in the first year after transplant despite the
routine use of acyclovir (ACV) prophylaxis, with the
potential for chronic and extensive mucocutaneous
lesions and for progression to disseminated disease
[1-3]. In contrast to immunocompetent patients, the
combination of prolonged antiviral prophylaxis or
treatment and impaired immune response can lead to
the development of ACV resistance, which has been
reported in up to 27% of allogeneic HCT recipients;
lower levels have been reported in patients with HIV
or hematologic malignancies, whereas resistance is
very infrequent in immunocompetent patients [4-6].
The current ASBMT guidelines recommend that “a
sufficiently high dose of acyclovir” be used to prevent
the emergence of antiviral resistance [7].
Most mutations conferring ACV resistance occur
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bmt.2010.06.020dosing regimens of ACV and its analogs ineffective
[8]. These viruses are typically sensitive to treatment
with foscarnet (FOS) and cidofovir (CID); however,
these drugs share substantial potential for nephrotoxi-
city, and resistance to FOS can develop quickly after
relatively short periods of use [9,10].
We describe here a series of allogeneic HCT recip-
ientswithACV-resistantHSV infection afterHCTwho
failed treatment with 1 or more conventional antiviral
therapies but responded to the administration of high-
dose continuous infusion of ACV. All patients received
antiviral prophylaxis with oral ACV 400 mg by mouth
twice daily for at least 100 days after transplantation.CLINICAL CASES
Case 1
Nine months following a T cell-depleted bone
marrow transplant from an unrelated donor (URD)
for acute myelogenous leukemia (AML) complicated
by acute graft-versus-host disease (aGVHD) of the
skin and gastrointestinal tract, a 37-year-old woman
was admitted with high fever and a month-long history
of severe genital ulcerations positive for HSV-2 by di-
rect fluorescent antibody testing (DFA) and culture,
which had progressed despite 400 mg of oral ACV 5
times per day, oral famciclovir, and 5 mg/kg intrave-
nous (i.v.) ACV 3 times daily over a 1-month period.
A plaque reduction assay (Viromed, Minnetonka,
MN) indicated that the HSV-2 isolate was resistant
to ACV and ganciclovir (GCV) but susceptible to
FOS (see Table 1 and Figure 1). Replacing ACV
with FOS resulted in a worsening of ulcerations and
severe neutropenia, prompting discontinuation of
FOS. After 5 doses of CID 5 mg/kg per week,259
Table 1. Summary of Case Reports
Immunosuppression MIC50 (mg/mL)†
Failed Treatment
Regimens‡
Cont. ACV
Dose mg/kg/day
Outcome, Time
to ResponseCase Age, Sex HCT Type* GVHD PRED Other HSV Type; Location ACV GCV FOS
1 37
F
TCD
URD
MA
Skin, GI
Grade 2
<0.5 mg/kg/day CsA HSV-2; Genitalia
Naris
10 30 22 ACV PO
FAM PO
ACV IV
FOS i.v.
CID i.v.
30 Resolved
6 weeks
2 47
F
URD
MA
Skin
Grade 4
<0.5-2 mg/kg/day TAC
MMF
HSV-2; Genitalia,
buttocks, thighs
>48 45 >200 ACV i.v.
FOS i.v.
45 Resolved
2 months
3 55
F
URD
MA
Skin
Grade 2
50 mg/day TAC
MMF
HSV-1; OP >48 30 >48 ACV i.v.
FOS i.v.
30 Resolved
1 week
4 44
F
URD
MA
Skin
Grade 4
60 mg/day TAC HSV-1; OP >48 30-50 >48 ACV i.v.
FAM PO
30-50 Partially resolved§
5 54
M
MRD
MA
None None CSA
ATG
HSV-1; Naris >48 30 >100 ACV PO
FAM PO
30 Resolved
1 week
6 52
M
MRD
NMA
Skin
Grade 4
1 mg/kg/day TAC HSV-1; OP 48 48 100 ACV i.v. 30 Resolved
1 week
HCT indicates hematopoietic cell transplant; GVHD, graft-versus-host disease; PRED, prednisone (oral); HSV, herpes simplex virus; MIC, minimum inhibitory concentration; ACV, acyclovir; GCV, ganciclovir; FOS,
foscarnet; CID, cidofovir; FAM, famciclovir; Cont., continuous; TCD, T cell depleted; URD, matched unrelated donor; MA, myeloablative; MRD, matched related donor; GI, gastrointestinal; CsA, cyclosporine; TAC,
tacrolimus; MMF, mycophenolate mofetil; ATG, antithymocyte globulin, OP, oropharynx.
*All patients received allogeneic transplants and HSV prophylaxis with oral ACV 400 mg twice daily.
†For case 1, resistance testing performed by plaque reduction assay (Viromed, MN). For all other cases, resistance testing performed clinical isolates via dye uptake method by Focus Diagnostics (Cypress, CA).
Breakpoints for resistance testing are 3 mg/mL for ACV and GCV and 100 mg/mL for FOS.
‡Dose ranges: ACV 400 mg by mouth 5 times daily to 10 mg/kg i.v. every 8 hours; CID 5 mg/kg weekly; FOS 40-50 mg/kg; FAM 1-3 g by mouth daily (in divided doses).
§Patient expired prior to resolution of lesions.
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Figure 1. Schematic of antiviral regimens used to treat ACV-resistant HSV disease. Summary of treatment beginning with clinical detection of infection
at time 0 and continuing through resolution of disease is shown for each patient. As shown in key below figure, circles represent oral ACV therapy,
triangles intermittent intravenous ACV, and arrows continuous intravenous ACV therapy. Cross indicates foscarnet, square cidofovir, diamond famci-
clovir, X ganciclovir, and hexagon valacyclovir therapy. Points where therapy stopped because of intolerance are indicated by red symbols.
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ment course was complicated by acute renal failure and
neutropenia, which recurred after rechallenge with
CID. Given the severity and persistence of disease,
combined therapy was then attempted despite the fact
that she had worsened while on foscarnet in the past:
high-dose continuous infusion ACV of 30 mg/kg/day
plus daily foscarnet was administered with eventual
complete resolution of herpetic lesions. However, she
developed extensive chronicGVHD (cGVHD), requir-
ing treatment with clofazimine, cyclosporine, and pred-
nisone, as well as total lymphoid irradiation (TLI),
which eventually led to her death.Case 2
A 47-year-old woman with a history of myelodys-
plastic syndrome (MDS) transformed to AML under-
went a matched related donor HCT complicated by
grade IV aGVHD of the skin and gastrointestinal tract
treated with tacrolimus, mycophenolate mofetil
(MMF), and prednisone 1 mg/kg orally twice per
day, as well as veno-occlusive disease (VOD). She
developed HSV-2-positive lesions in her gluteal fold
and despite ACV at 5 mg/kg i.v. every 8 hours, addi-
tional ulcerative lesions developed on her vaginal labia,
perineum, buttocks, and upper thighs. Replacement of
ACV with FOS resulted in modest improvement;
however, she was readmitted 2 weeks later with new
vaginal lesions, fatigue, malaise, severe constipation,
confusion, and a serum sodium of 114 (Figure 2). After
a brief interruption of antiviral therapy, combinationantiviral therapy was instituted with ACV 5 mg/kg
i.v. twice daily, adjusted for her renal function, and
low-dose FOS 2 g daily. Nevertheless, her lesions
failed to improve and repeat susceptibility testing re-
vealed resistance to ACV, FOS, and GCV (Table 1).
Because of the severity and large extent of involvement
of her lesions, a higher dose of ACV was chosen and
she was treated with high-dose continuous infusion
of ACV 45 mg/kg/day for over 2 months with com-
plete resolution of her extensive skin lesions.Case 3
A 55-year-old woman with MDS and AML under-
went HCT following a myeloablative preparative
regimen complicated by aGVHD of the skin, human
herpes virus-6 viremia, paroxysmal atrial fibrillation,
presumed aspergillosis, and catheter-related right in-
ternal jugular deep vein thrombosis. She subsequently
developed failure to thrive in the setting of extensive
cGVHD resulting in her treatment with oral MMF,
prednisone 50 mg daily, and tacrolimus. Two years
after HCT, while receiving ACV 400 mg by mouth
twice daily as prophylaxis, she developed extensive le-
sions of her lips, buccal mucosa, and palate, confirmed
to be HSV-1 by DFA and culture. Despite an increase
of the ACV dose to 400 mg 5 times daily for 2 weeks
and then 5 mg/kg i.v. 3 times daily, her HSV-1 infec-
tion continued to progress with new DFA- and
culture-positive lesions on her lips. ACV was replaced
by FOS with i.v. immunoglobulin (500 mg/kg) every
other day for 3 doses. Nine days after the initiation
Figure 2. Extensive genital HSV lesions in an HCT recipient. Posterior
aspect of genital lesions in case 2, prior to the initiation of continuous
high-dose ACV therapy. Large, near confluent, ulcerated lesions involving
the labia, gluteal cleft, and buttocks are shown; lesions also extended
anteriorly from the vulva to the thighs bilaterally. These lesions completely
resolved after 2 months of continuous infusion ACV therapy.
262 Biol Blood Marrow Transplant 17:259-264, 2011J. H. Kim et al.of FOS, modest improvement was noted in her pain
and the extent of the lesions. However, she developed
acute renal insufficiency resulting in interruptions in
FOS therapy and recurrence of severe herpetic muco-
sitis, fevers, and pancytopenia, at which time she was
noted to also have cytomegalovirus (CMV) viremia.
She then received i.v. GCV for CMV viremia and
high-dose continuous infusion of ACV 30 mg/kg/day
for HSV as her HSV isolate was resistant to GCV
(Table 1). Her CMV viremia cleared rapidly and she
was continued on high dose ACV alone with eventual
complete resolution of her herpetic mucositis.Case 4
A 44-year-old woman received a URD HCT for
essential thrombocytosis and AML complicated by
duodenal perforation, VOD, acute renal failure, and
GVHD of the skin treated with tacrolimus and high
dose prednisone alternating between 60 mg and 50
mg every other day. Ninety days after transplantation,
while taking oral ACV 400 mg twice daily, she devel-
oped large tongue and buccal ulcers positive for
HSV-1 by DFA.Her lesions worsened despite sequen-
tial trials of oral ACV 400 mg 3 times daily, i.v. ACV
5 mg/kg every 8 hours, and oral famciclovir 1000 mg
3 times daily. After susceptibility testing revealed
that the HSV-1 isolate was resistant to ACV and
FOS (see Table 1), she received high-dose continuous
infusion ACV, 30 mg/kg/day for 1 week without sig-
nificant improvement, then increased to 45 mg/kg/
day, resulting in modest improvement and resolution
of her dysphagia. ACV was held for 5 days to deter-
mine if the drug was contributing to new leukopenia,during which time topical CID (3% solution twice
daily, swish and spit) was administered for 1 week.
However, lesions worsened significantly with severe
pain and dysphagia and high-dose continuous infusion
ACV was restarted at 50 mg/kg/day with resolution of
her dysphagia and improvement of her lesions. She
died a week later from respiratory failure not thought
to be related to her oral HSV infection.
Case 5
A 25-year old man underwent HCT following
a nonmyeloablative preparative regimen of antithymo-
cyte globulin (ATG) and cyclophosphamide for amega-
karyocytic thrombocytopenia, which was complicated
by Epstein-Barr virus (EBV)-associated lymphoproli-
ferative disorder. He developed a painful crusted lesion
on his left naris while receiving prophylactic dosing of
oral ACV. The lesion progressed despite oral ACV 5
times per day for 2 weeks followed by famciclovir for 1
week. He developed a second lesion on his left cheek
prompting the institution of high-dose continuous infu-
sionACV30mg/kg/daywith rapid resolutionof his skin
lesions.HisHSV-1 isolatewas confirmed to be resistant
to ACV, FOS, and ganciclovir.
Case 6
A 52-year-old man with extensive cGVHD of the
skin 2 years after matched-related donor nonmyeloa-
blative HCTwith an ATG- and TLI-based condition-
ing regimen for anaplastic T cell lymphoma and
history of Rhizopus pneumonia, was admitted to the
hospital with fever and dyspnea and found to have
pneumonia due to 2009 H1N1 influenza. He required
a prolonged stay in the intensive care unit and under-
went intubation for respiratory support; he was treated
with oseltamivir, amantadine, ribavirin, and cortico-
steroids. Two months into his hospitalization he was
noted to have oral mucosal lesions, which were positive
for HSV by DFA testing while he was on oral cortico-
steroid therapy at 1 mg/kg/day. He was started on i.v.
ACV 5 mg/kg 3 times daily, but after 2 weeks of ther-
apy had persistent lesions as well as a new lesion on his
tongue, which also tested positive for HSV by DFA.
Viral cultures grew HSV-1, and sensitivity testing
revealed ACV resistance (see Table 1); he was treated
with 1 week of continuous i.v. ACV therapy at 30
mg/kg/day with near resolution of tongue andmucosal
regions, then transitioned to oral famvir therapy 1 g 3
times daily for an additional 4 weeks with complete
resolution of oral lesions.RESULTS
Six HCT recipients experienced severe HSV dis-
ease requiring i.v. antiviral therapy and did not respond
or could not tolerate conventionally dosed,
Biol Blood Marrow Transplant 17:259-264, 2011 263Continuous Infusion High-Dose Acyclovirintermittent, therapywith eitherACVorFOS (Figure 1
and Table 1). Five of 6 had undergone myeloablative
transplants, and 5 of 6 experienced GVHD, which re-
quired the administration of systemic immunosuppres-
sive medication at the time of development of HSV
disease. All had ACV resistance, the majority of which
with very high levels of resistance to both ACV and
FOS. With the exception of the patient described in
case 1, all the patients in this serieswere treated for their
HSV disease with high-dose continuous infusion ACV
alone with good clinical response. In this case, it is pos-
sible that her response was because of synergy between
FOS and ACV, although it is notable that she had pre-
viously worsened on FOS monotherapy (Figure 1).
For most of the cases described here, clinical re-
sponse was seen within 72 hours of continuous ACV
administration, during a time period where there
were no changes in the patients’ immunosuppressive
regimens and no notable difference in immune cell
levels as determined by flow cytometry before or after
the treatment period (data not shown). For patient 2,
although there were no significant changes in her im-
munosuppressive medications during her treatment
course, it is possible that the concurrent resolution of
her skin GVHD may have had a positive impact on
the healing of her herpetic lesions. It is striking that
for this patient, despite the extensive nature of her dis-
ease, the administration of continuously dosed ACV at
levels equivalent to previous intermittent dosing levels
resulted in complete resolution of herpetic lesions.
In each case, continuous ACV dosing was well tol-
erated, even in patients with renal insufficiency and
concurrent administration of systemic immunosup-
pressive therapies such as cyclosporine and tacrolimus.
No toxicity, including episodes of neutropenia, exacer-
bations of other cytopenias, or worsening in renal
function, was observed during continuous ACV ad-
ministration. No substantive changes in dosages of
concomitant medications were required during
continuous ACV therapy.DISCUSSION
ACV resistance is not uncommon, has previously
been described as a not infrequent problem in the
HCT population, and is often seen in the associated
setting of prolonged ACV prophylaxis or treatment
in a patient with impaired antiviral immunity. The
patients described here were either receiving immuno-
suppressive therapy either for treatment of GVHD
(patients 1-4 and 6) or for GVHD prophylaxis in the
first 100 days after transplantation (patient 5). Because
of concerns regarding low serum levels using the ACV
400 mg twice daily prophylaxis dose used in these pa-
tients, our center is now routinely using ACV 400mg 3
times daily, as other authors have described improvedoutcomes with higher doses and longer periods of
antiviral administration [11]. In addition, studies of
valacyclovir prophylaxis HCT patients compared
against historic controls receiving oral acyclovir have
shown similar performance in terms of safety and effi-
cacy in prevention of HSV mucositis [12].
A search of the PubMed database revealed only 2
small case series and 1 case report showing the success
of continuous infusion high-dose ACV for severe
HSV infection [13-15]. In 1 report, 3 patients with
mucocutaneous lesions because of HSV improved
after receiving high-dose continuous infusion at 29
to 150 mg/kg ACV per day, with steady-state concen-
trations targeted between 20 to 80 mmol/liter for 8 to
46 days (equivalent to 4.5 to 18.2 mg/L using a conver-
sion factor of 4.4 [16]). The patient with the highest
ranges of serum drug level appeared to have the most
rapid improvement [13]. In a second report, 2 patients
with acquired immunodeficiency syndrome with
severe ulcerative proctitis because of ACV-resistant
HSV were successfully treated with 6 weeks of high-
dose, continuous acyclovir infusion (1.5-2.0 mg/kg/
hour, 36 to 48 mg/kg/day). These patients achieved
plasma ACV levels between 4.5 and 6.75mg/Lwithout
adverse events [14]. One case report of an 8-year-old
patient with Wiskott-Aldrich syndrome and severe
conjunctivitis dermatitis not responding to intermit-
tent dosing with i.v. ACV was successfully treated
with continuous infusion at 125 mg/hour, achieving
plasma levels between 9.0 and 10.3 mg/L [15]. It is
difficult to postulate what serum levels were achieved
with our similar dosing parameters in our patient
population of HCT patients.
It is not known whether serum ACV levels consis-
tently correlatewith clinical outcome.Althoughdata re-
garding ACV pharmacokinetics in these patients would
have greatly strengthened the possibility of understand-
ing why high-dose continuous infusion was successful,
the unique observations made in our series of patients
is nonetheless helpful in formulating hypotheses regard-
ing possible mechanisms by which this dosing schedule
overcomes ACV resistance. Four of 6 patients failed to
improve when receiving the same total daily dose given
on an intermittent dosing schedule. Thus, it is possible
that in the treatment of ACV-R HSV, ensuring higher
steady-state and/or a greater area under the curve is
more important than high peak plasma concentration.
Favorable pharmacokineticsmay result inhigherplasma
levels, which may be able to overcome altered substrate
specificity or even bypass the need for viral kinase
phosphorylation when mutations result in missing or
truncated viral TK.
Interestingly, 4 of the 6 isolates demonstrated in
vitro resistance to foscarnet, suggesting that mutations
were not limited to the thymidine kinase (TK) gene
but may have involved DNA polymerase as well,
although genotyping has not been performed on these
264 Biol Blood Marrow Transplant 17:259-264, 2011J. H. Kim et al.isolates. There is evidence that significant changes in
viral TK and DNA polymerase can affect viral fitness
[4], and therefore in a heterogeneous population of
viruses, the effects of higher or sustained ACV levels
may affect the ratio of wild-type to mutant strains
resulting in attenuation of clinical disease.
Without serum levels, it is difficult to determine
the exact pharmacologic determinate of clinical suc-
cess for these 6 patients. It is also possible that immu-
nologic factors such as improvement in T cell function
could also have played a role in resolution of HSV in-
fection.However, absolute lymphocyte counts, CD41,
CD81, and CD191/201 counts were far below the
normal range in all patients included in this analysis
(data not shown).
In 1 patient (case 2), improvement in her GVHD
may have resulted in improved overall lymphocyte
responses; however, in none of the patients were the
immunosuppressants weaned during the period of
antiviral therapy. In the remainder of patients, the
rapidity of response to continuous infusion ACV
makes it unlikely that there had been any significant
improvement in immune function.CONCLUSION
Continuous infusion of high-dose ACV is a well-
tolerated alternative treatment for patients with infec-
tion because of ACV-resistant or multidrug resistant
HSV who are failing or intolerant of therapy with
standard-dose intermittent infusion of ACV, FOS,
CID, or ganciclovir. We are currently investigating
the mechanisms by which the sustained levels of
ACV provide this therapeutic advantage.ACKNOWLEDGMENTS
The authors thank Dianne M. Brundage for her
helpful input regarding pharmacokinetics.
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Yahav D, Gafter-Gvili A, Muchtar E, et al. Antiviral prophylaxis
in haematological patients: systematic review and meta-analysis.
Eur J Cancer. 2009;45:3131-3148.
2. Wood MJ. Viral infections in neutropeniadcurrent problems
and chemotherapeutic control. J Antimicrob Chemother. 1998;
41(Suppl D):81-93.
3. Sable CA, Donowitz GR. Infections in bone marrow transplant
recipients. Clin Infect Dis. 1994;18:273-281. quiz 282e274.
4. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes
simplex virus resistance to acyclovir and penciclovir after two de-
cades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-128.
5. Morfin F, Thouvenot D. Herpes simplex virus resistance to
antiviral drugs. J Clin Virol. 2003;26:29-37.
6. Chen Y, ScieuxC,Garrait V, et al. Resistant herpes simplex virus
type 1 infection: an emerging concern after allogeneic stem cell
transplantation. Clin Infect Dis. 2000;31:927-935.
7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for
preventing infectious complications among hematopoietic cell
transplantation recipients: a global perspective. Biol Blood
Marrow Transplant. 2009;15:1143-1238.
8. Darville JM, Ley BE, Roome AP, Foot AB. Acyclovir-resistant
herpes simplex virus infections in a bonemarrow transplant pop-
ulation. Bone Marrow Transplant. 1998;22:587-589.
9. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE,
Milligan DW. Resistance to antiviral drugs in herpes simplex virus
infections among allogeneic stem cell transplant recipients: risk fac-
tors and prognostic significance. J Infect Dis. 2000;181:2055-2058.
10. Danve-Szatanek C, AymardM,Thouvenot D, et al. Surveillance
network for herpes simplex virus resistance to antiviral drugs:
3-year follow-up. J Clin Microbiol. 2004;42:242-249.
11. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of
long-term suppressive acyclovir after hematopoietic stem-cell
transplantation: impact on herpes simplex virus (HSV) disease
and drug-resistant HSV disease. J Infect. Dis. 2007;196:266-270.
12. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical
utility of oral valacyclovir compared with oral acyclovir for the
prevention of herpes simplex virus mucositis following autolo-
gous bone marrow transplantation or stem cell rescue therapy.
Bone Marrow Transplant. 2003;31:51-55.
13. Fletcher CV, Englund JA, Bean B, Chinnock B, Brundage DM,
Balfour HH Jr.. Continuous infusion of high-dose acyclovir for
serious herpesvirus infections. Antimicrob Agents Chemother.
1989;33:1375-1378.
14. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of
resistant herpes simplex virus with continuous-infusion acyclo-
vir. JAMA. 1990;263:1662-1664.
15. Bean B, Fletcher C, Englund J, Lehrman SN, Ellis MN.
Progressive mucocutaneous herpes simplex infection because
of acyclovir-resistant virus in an immunocompromised patient:
correlation of viral susceptibilities and plasma levels with
response to therapy. Diagn Microbiol Infect Dis. 1987;7:199-204.
16. Laskin OL. Acyclovir. Pharmacology and clinical experience.
Arch Intern Med. 1984;144:1241-1246.
